CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$59.99 USD
+2.12 (3.66%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $60.03 +0.04 (0.07%) 4:40 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
CRISPR Therapeutics AG [CRSP]
Reports for Purchase
Showing records 41 - 60 ( 214 total )
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
3Q22: BLA Rolling Submission Begins This Month
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Regulatory Submission for Hemoglobinopathy Cure to Begin in November
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Vertex?s Acquires ViaCyte. Friend or Foe in Diabetes?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Company: CRISPR Therapeutics AG
Industry: Medical - Biomedical and Genetics
Functional Cure of 75 Patients Having Hemoglobinopathies Presented at Hematology Meeting
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T